نتایج جستجو برای: renoprotection

تعداد نتایج: 483  

Journal: :Acta Physiologica 2016

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2006
Karen A Griffin Anil K Bidani

Recent guidelines for management of patients with chronic kidney disease recommend both lower optimal BP targets and agents that block the renin-angiotensin system (RAS) for specific additional BP-independent renoprotection. Although there are other compelling rationales to use RAS blockade in patients with chronic kidney disease, including its antihypertensive effectiveness and ability to coun...

Journal: :iranian red crescent medical journal 0
mahmoud rafieian-kopaei medical plants research center, shahrekord university of medical sciences, shahrekord, ir iran hamid nasri department of nephrology, division of nephropathology, isfahan university of medical sciences, isfahan, ir iran; department of nephrology, division of nephropathology, isfahan university of medical sciences, isfahan, ir iran. tel: +98-3112208081, fax: +98-3112235043

Journal: :World Journal of Nephrology 2016

Journal: :Nature Reviews Nephrology 2020

Journal: :The Netherlands journal of medicine 2010
L Vogt G D Laverman G Navis

Before the introduction of renin-angiotensin-aldosterone system (RAAS) inhibitors in the 1980s, non-steroidal anti-inflammatory drugs (NSAIDs) were the only class of drugs available for the reduction of symptomatic proteinuria. Long-term data from those days suggested sustained renoprotective properties in proteinuric chronic kidney disease (CKD), but this potential has not been further explore...

Journal: :Kidney International 2000

Journal: :Kidney International 2005

2014
Xuan Xiong Wenjuan Mei Yanyun Xie Jishi Liu Miaomiao Lu Xiongqun Peng Congyin Yang Xin Zhang Mingyan Xie Renna Luo Xiangning Yuan Ling Huang Lin Wu Jiao Qin Yu Peng Xiujie Jia Gaoyun Hu Damu Tang Lijian Tao

Diabetic nephropathy (DN) remains the leading cause of end-stage renal disease (ESRD), a situation that is in part attributable to the lack of effective treatments. Fluorofenidone is a newly developed reagent with anti-fibrotic activity. While fluorofenidone was previously demonstrated to possess renoprotection from DN pathogenesis in db/db mice, the protective process and its underlying mechan...

Journal: :Clinical and Experimental Nephrology 2018

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید